NCT04158336 2026-03-18
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Completed
Clinical Trials
19 trialsNCT05735366 2026-03-10
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Chugai Pharmaceutical
Phase 1 Completed
NCT04175847 2026-01-07
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Completed
NCT04617314 2026-01-06
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1 Completed
NCT05174585 2026-01-06
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT05991349 2025-11-25
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Completed
NCT06310655 2025-11-10
PARTy
Washington University School of Medicine
Phase NA Completed
NCT01239381 2025-09-30
Individualized Stereotactic Body Radiotherapy of Liver Metastases
Massachusetts General Hospital
Phase NA Completed
NCT05109832 2025-09-16
A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects
Impact Therapeutics, Inc.
Phase 1 Completed
NCT05390944 2025-09-16
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
Phase 1 Completed
NCT05391048 2025-09-16
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Impact Therapeutics, Inc.
Phase 1 Completed
NCT03195478 2025-09-15
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04937153 2025-07-16
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
Genmab
Phase 1 Completed
NCT05323045 2025-07-09
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
Byondis B.V.
Phase 1 Completed
NCT07030439 2025-06-22
A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
Impact Therapeutics, Inc.
Phase 1 Completed
NCT07019194 2025-06-13
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
Phase 1 Completed
NCT03517917 2025-05-23
Prospective Tissue Collection Research Protocol
AstraZeneca
Completed
NCT04720976 2025-04-11
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02454010 2025-04-04
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1 Completed